Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL29358144 | 1.00 | NAPRT (0.69) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Pyridine SCHEMBL27285374 | 0.96 | TSHR (0.64) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Pyridine SCHEMBL28296779 | 0.86 | NAPRT (0.60) | NAPRTTSHRTDP1NOTUMMEN1 | |
| SCHEMBL34466311 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Benzene SCHEMBL1261317 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Pyridine SCHEMBL16 | 0.83 | — | — | |
| Pyridine SCHEMBL933604 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 | |
| SCHEMBL3052767 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Pyridine SCHEMBL180431 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 | |
| Benzene SCHEMBL10751789 | 0.83 | TSHR (1.00) | NAPRTTSHRTDP1NOTUMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084614-A | Preparation method of 11-dodecyn-1-ol | 杭州励德生物科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023225645-A1 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | P2 SCIENCE, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230202996-A1 | SYNTHETIC METHODS FOR MAKING CARBOXYLIC ACIDS, ESTERS AND LACTONES | P2 SCIENCE, INC. | 2023-06-29 | — | — | US | claimed |
| WO-2023122724-A1 | IMPROVED SYNTHETIC METHODS FOR MAKING CARBOXYLIC ACIDS, ESTERS AND LACTONES | P2 SCIENCE, INC. (US) | 2023-06-29 | — | — | WO | claimed |
| CN-116348460-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116323594-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3613732-A1 | PROCESS FOR PREPARING (E2)-CIS-6,7-EPOXY-2-NONENAL | Shin-Etsu Chemical Co., Ltd. (JP) | 2020-02-26 | — | — | EP | claimed |
| CN-106146339-B | 5 epimers, preparation method and the usages of aliskiren | 华润双鹤药业股份有限公司 | 2018-02-23 | — | — | CN | claimed |
| EP-2865666-B1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-31 | — | — | EP | claimed |
| US-9567300-B2 | Hexahydropentaleno derivatives, preparation method and use in medicine thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-14 | — | — | US | claimed |
| US-4239689-A | Total synthesis of the utero-evacuant substance d,l-zoapatanol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1980-12-16 | — | — | US | claimed |
| EP-0020058-A1 | Total synthesis of (1RS, 4SR, 5RS)-4-(4,8-dimethyl-5-hydroxy-7-nonenyl)-4-methyl-3,8-dioxabicyclo (3.2.1) octane-1-acetic acid, and intermediates | ORTHO PHARMACEUTICAL CORPORATION (US) | 1980-12-10 | — | — | EP | claimed |
| US-4237055-A | Synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid | ORTHO PHARMACEUTICAL CORPORATION (US) | 1980-12-02 | — | — | US | claimed |
| US-4237054-A | Total synthesis of (1RS,4SR,5RS)-4-(4,8-dimethyl-5-hydroxy-7-nonenyl)-4-methyl-3,8-dioxabicyclo[3.2.1] octane-1-acetic acid | ORTHO PHARMACEUTICAL CORPORATION (US) | 1980-12-02 | — | — | US | claimed |
| US-4221717-A | Total synthesis of the utero-evacuant substance D,L-zoapatanol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1980-09-09 | — | — | US | claimed |
| EP-0002851-A1 | Novel intermediate in the preparation of cyclopropylcarboxylate esters and process for its manufacture | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1979-07-11 | — | — | EP | claimed |
| US-4127651-A | ZOAPATLE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-11-28 | — | — | US | claimed |
| US-4112078-A | ACYLATION, REDUCTION, ZOAPATLE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-4059585-A | Process for preparing an intermediate for CNS depressants | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-11-22 | — | — | US | claimed |
| US-4000261-A | 5-EPI-4,6-DI-O-(AMINOGLYCOSYL)-2-DEOXYSTREPTAMINES, METHODS FOR THEIR MANUFACTURE AND INTERMEDIATES USEFUL THEREIN, METHODS FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202996-A1 | SYNTHETIC METHODS FOR MAKING CARBOXYLIC ACIDS, ESTERS AND LACTONES | FDFT1, DLST, PCMT1 | NAPRT 153/4885TSHR 3012/4885TDP1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.